Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study

Simple item page
dc.contributor.authorJara, Alejandro
dc.contributor.authorUndurraga, Eduardo A.
dc.contributor.authorFlores, Juan Carlos
dc.contributor.authorZubizarreta, Jose R.
dc.contributor.authorGonzalez, Cecilia
dc.contributor.authorPizarro, Alejandra
dc.contributor.authorOrtuno-Borroto, Duniel
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorLeo, Katherinne
dc.contributor.authorParedes, Fabio
dc.contributor.authorBralic, Tomas
dc.contributor.authorVergara, Veronica
dc.contributor.authorLeon, Francisco
dc.contributor.authorParot, Ignacio
dc.contributor.authorLeighton, Paulina
dc.contributor.authorSuarez, Pamela
dc.contributor.authorRios, Juan Carlos
dc.contributor.authorGarcia-Escorza, Heriberto
dc.contributor.authorAraos, Rafael
dc.date.accessioned2024-01-10T12:37:19Z
dc.date.available2024-01-10T12:37:19Z
dc.date.issued2023
dc.description.abstractBackground Policymakers urgently need evidence to adequately balance the costs and benefits of mass vaccination against COVID-19 across all age groups, including children and adolescents. In this study, we aim to assess the effectiveness of CoronaVac's primary series among children and adolescents in Chile. Methods We used a large prospective national cohort of about two million children and adolescents 6-16 years to estimate the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in preventing laboratory-confirmed symptomatic SARS-CoV-2 infection (COVID-19), hospitalisation, and admission to an intensive care unit (ICU) associated with COVID-19. We compared the risk of individuals treated with a complete primary immunization schedule (two doses, 28 days apart) with the risk of unvaccinated individuals during the follow-up period. The study was conducted in Chile from June 27, 2021, to January 12, 2022, when the SARS-CoV-2 Delta variant was predominant but other variants of concern were co-circulating, including Omicron. We used inverse probability-weighted survival regression models to estimate hazard ratios of complete immunization over the unvaccinated status, accounting for time-varying vaccination exposure and adjusting for relevant demographic, socioeconomic, and clinical confounders.Findings The estimated adjusted vaccine effectiveness for the inactivated SARS-CoV-2 vaccine in children aged 6-16 years was 74.5% (95% CI, 73.8-75.2), 91.0% (95% CI, 87.8-93.4), 93.8% (95% CI, 87.8-93.4) for the prevention of COVID-19, hospitalisation, and ICU admission, respectively. For the subgroup of children 6-11 years, the vaccine effectiveness was 75.8% (95% CI, 74.7-76.8) for the prevention of COVID-19 and 77.9% (95% CI, 61.5-87.3) for the prevention of hospitalisation.Interpretation Our results suggest that a complete primary immunization schedule with the inactivated SARS-CoV-2 vaccine provides effective protection against severe COVID-19 disease for children 6-16 years.Copyright & COPY; 2023 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
dc.fechaingreso.objetodigital01-04-2024
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.lana.2023.100487
dc.identifier.issn2667-193X
dc.identifier.urihttps://doi.org/10.1016/j.lana.2023.100487
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76814
dc.identifier.wosidWOS:001029180200001
dc.information.autorucFacultad de Medicina; Rios Bustamante, Juan Carlos; S/I; 104168
dc.language.isoen
dc.nota.accesocontenido completo
dc.publisherELSEVIER
dc.revistaLANCET REGIONAL HEALTH-AMERICAS
dc.rightsacceso abierto
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectVaccine effectiveness
dc.subjectInactivated SARS-CoV-2 vaccine
dc.subjectmRNA vaccine
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study
dc.typeartículo
dc.volumen21
sipa.codpersvinculados104168
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-04-01. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents.pdf
Size:
383.53 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas